Is NCT06712407 recruiting?

Yes, NCT06712407 is currently recruiting. This iga nephropathy study is enrolling participants at 37 locations.

What is the status of NCT06712407?

NCT06712407 is currently recruiting. This is a Clinical Trial trial for iga nephropathy sponsored by Calliditas Therapeutics AB. Status verified Feb 5, 2026 via ClinicalTrials.gov.

Where is NCT06712407 enrolling participants?

NCT06712407 has 37 active sites including Birmingham, Alabama; Glendale, Arizona; Fresno, California and 34 more locations.

Who is eligible for NCT06712407?

This iga nephropathy trial is targeting 60 participants. Detailed eligibility criteria including age requirements and medical history are listed on this page.

Who can participate in this IgA Nephropathy study?

Eligibility varies by study, but generally includes adults diagnosed with IgA Nephropathy who meet specific medical criteria. Complete the interest form above to learn if you may qualify.

Is the study available in Birmingham, Alabama?

Yes! This study has active research sites in Birmingham, Glendale, Orange. When you express interest, you'll be connected with the site nearest to you.

What are the benefits of joining a clinical trial for IgA Nephropathy?

Participants often receive: access to new treatments before they're widely available, close monitoring by medical professionals, study-related care at no cost, and the opportunity to contribute to medical research.

⚡Your ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

NCT06712407 RECRUITINGIRB Ready

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

(NefXtend)

Express Your Interest Today

Interested in learning more? Complete the form below.

First Name *

Last Name *

Email Address *

Phone Number *

ZIP Code *

Age Range *

Preferred Location

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

No-Cost Study Care
Advance Medical Science
Contribute to groundbreaking research
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel (varies by study)
Help Others
Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

1Submit this form
2Phone screening
3In-person assessment if eligible
4Begin participation

About This Study

The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice.

Who Can Participate

Inclusion Criteria

Diagnosed IgAN with biopsy verification 2. Female or male participants ≥18 years of age 3. Completion of 9 months of treatment with TARPEYO® 16 mg QD at the Baseline visit 4. Access to retrospective local laboratory assessment data on UPCR and serum creatinine. Available retrospective data should include at least 1 assessment timepoint within 3 months prior to the first dose of TARPEYO® commercial treatment 5. Proteinuria at Screening based on 2 consecutive measurements (24-hour urine collection) after informed consent, separated by at least 1 week and calculated by the central laboratory. Both samples of the same parameter must show either of the following:

Proteinuria ≥0.5 g per day (≥500 mg per day) in 2 consecutive measurements, or

UPCR ≥0.3 g/gram in 2 consecutive measurements 6. On stable treatment with renin-angiotensin system (RAS) inhibitor therapy for at least 8 weeks prior to the Baseline visit. A stable dose is defined as a dose wit

❓ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

📋

Study Type

INTERVENTIONAL

👥

Target Enrollment

60 participants

⚧

Gender

ALL

🏢

Sponsor

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

🔒 Secure · 🏥 Expert Care

Find More IgA Nephropathy Trials by City

Browse all iga nephropathy clinical trials in these cities — not just this study.

Birmingham, Alabama Glendale, Arizona Orange, California San Francisco, California Stanford, California Aurora, Colorado

Browse More Trials by Condition

IgA Nephropathy Trials Pulmonary Hypertension Trials Geographic Atrophy Trials All Conditions →

Looking for IgA Nephropathy Treatment in Birmingham?

Join others in Alabama exploring innovative treatment options through clinical research

IgA Nephropathy Treatment Options in Birmingham, Alabama

If you're searching for IgA Nephropathy treatment in Birmingham, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Birmingham, Glendale, Orange and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with IgA Nephropathy. All study-related care is provided at no cost to participants.

Local Sites

3 locations in Alabama

Now Enrolling

Up to 60 participants

Quick Start

Screening available now

Why Consider a Clinical Trial for IgA Nephropathy?

Potential Benefits

✓Access to new treatment approaches before public availability
✓Close monitoring by experienced medical professionals
✓Study-related care provided at no cost
✓Contribute to medical research for IgA Nephropathy

What to Expect

→Initial screening to determine eligibility
→Regular check-ups and monitoring visits
→Possible compensation for time and travel
→You can withdraw at any time

Frequently Asked Questions About This IgA Nephropathy Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06712407. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.